{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:47:22Z","timestamp":1788961642037,"version":"build-2803163510"},"reference-count":21,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Personalized prognostic assessment in extensive-stage small cell lung cancer (ES-SCLC) necessitates a comprehensive understanding of systemic inflammatory markers and their impact on survival outcomes. This study aimed to evaluate the prognostic significance of a novel Inflammatory Prognostic Index (IPI) score, derived from four inflammation-related biochemical markers\u2014albumin, C-reactive protein (CRP), neutrophils, and lymphocytes\u2014in patients with ES-SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients diagnosed with ES-SCLC were eligible if adequate clinical, pathological, and follow-up data were available. The IPI score was derived using the formula: C-reactive protein \u00d7\u00a0neutrophil-to-lymphocyte ratio (NLR)\/serum albumin. The threshold value for the IPI score was identified using receiver operating characteristic (ROC) curve analysis within the cohort and was applied in an exploratory manner. Based on the predefined cut-off, patients were stratified into low- and high-IPI groups. The log-rank test was used to compare survival times, while Kaplan\u2013Meier curves and Cox regression analyses assessed variables associated with long-term survival. Overall survival (OS) served as the primary endpoint, and progression-free survival (PFS) was evaluated as a secondary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with a high IPI score had a mean OS of 9 months (95% CI [4.8\u201313.2]), while those with a low IPI score had a mean OS of 23 months (95% CI [11.4\u201334.6]), a statistically significant difference (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.005). The prognostic significance of IPI was confirmed in both univariate (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.003) and multivariate (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.012) analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The IPI score in ES-SCLC patients was associated with prognosis, with a high IPI score indicating poorer OS. These findings should be considered hypothesis-generating and warrant validation in larger prospective cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.20343","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:56:05Z","timestamp":1762764965000},"page":"e20343","source":"Crossref","is-referenced-by-count":2,"title":["IPI score as a new prognostic index in extensive stage small cell lung cancer"],"prefix":"10.7717","volume":"13","author":[{"given":"Ahmet Burak","family":"A\u011fao\u011flu","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u015eahbazlar","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atike P\u0131nar","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"10.7717\/peerj.20343\/ref-1","author":"Bennett","year":"2020","journal-title":"ClinicalKey: a comprehensive medical reference [Internet]"},{"issue":"3","key":"10.7717\/peerj.20343\/ref-2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"15_suppl","key":"10.7717\/peerj.20343\/ref-3","doi-asserted-by":"publisher","first-page":"e20623","DOI":"10.1200\/JCO.2016.34.15_suppl.e20623","article-title":"C-reactive protein (CRP) as a predictive marker for immunotherapy in lung cancer","volume":"34","author":"Brustugun","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.7717\/peerj.20343\/ref-4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1183\/09031936.00105009","article-title":"Treatment of extensive-stage small cell lung carcinoma: current status and future prospects","volume":"35","author":"Demedts","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.7717\/peerj.20343\/ref-5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12094-015-1367-0","article-title":"A new inflammatory prognostic index based on C-reactive protein, the neutrophil-to-lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases","volume":"18","author":"Dirican","year":"2016","journal-title":"Clinical and Translational Oncology"},{"issue":"36","key":"10.7717\/peerj.20343\/ref-6","first-page":"45","article-title":"Can albumin bilirubin ratio and inflammatory prognostic index be a new marker determining survival in metastatic pancreatic cancer?","volume":"1","author":"Ekinci","year":"2021","journal-title":"Gulf Journal of Oncology"},{"issue":"10","key":"10.7717\/peerj.20343\/ref-7","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.29271\/jcpsp.2022.10.1288","article-title":"Inflammatory prognostic index in metastatic renal carcinoma treated with nivolumab","volume":"32","author":"Ekinci","year":"2022","journal-title":"Journal of the College of Physicians and Surgeons Pakistan"},{"issue":"1","key":"10.7717\/peerj.20343\/ref-8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12029-021-00642-w","article-title":"Could the inflammatory prognostic index predict the efficacy of regorafenib in patients with metastatic colorectal cancer?","volume":"53","author":"Erdo\u011fan","year":"2021","journal-title":"Journal of Gastrointestinal Cancer"},{"issue":"6","key":"10.7717\/peerj.20343\/ref-9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"2","key":"10.7717\/peerj.20343\/ref-10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nm.2084","article-title":"Neutrophil elastase\u2014mediated degradation of IRS-1 accelerates lung tumor growth","volume":"16","author":"Houghton","year":"2010","journal-title":"Nature Medicine"},{"issue":"8","key":"10.7717\/peerj.20343\/ref-11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/1759-7714.13905","article-title":"Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: a comprehensive analysis of 358 patients","volume":"12","author":"Huang","year":"2021","journal-title":"Thoracic Cancer"},{"issue":"10","key":"10.7717\/peerj.20343\/ref-12","doi-asserted-by":"publisher","first-page":"5718","DOI":"10.21037\/jtd-20-1739","article-title":"The prognostic value of pretreatment prognostic nutritional index in patients with small cell lung cancer and its influencing factors: a meta-analysis of observational studies","volume":"12","author":"Jiang","year":"2020","journal-title":"Journal of Thoracic Disease"},{"key":"10.7717\/peerj.20343\/ref-13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3389\/fimmu.2024.1327449","article-title":"Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer","volume":"15","author":"Kuang","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"7203","key":"10.7717\/peerj.20343\/ref-14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.7717\/peerj.20343\/ref-15","article-title":"Small cell lung cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)","author":"National Comprehensive Cancer Network\u00a0(NCCN)","year":"2024"},{"issue":"9","key":"10.7717\/peerj.20343\/ref-16","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.7150\/jca.75622","article-title":"A 2022 update on extensive-stage small-cell lung cancer (SCLC)","volume":"13","author":"Oronsky","year":"2022","journal-title":"Journal of Cancer"},{"issue":"5","key":"10.7717\/peerj.20343\/ref-17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4046\/trd.2014.76.5.218","article-title":"Progression-free survival: an important prognostic marker for long-term survival of small cell lung cancer","volume":"76","author":"Park","year":"2014","journal-title":"Tuberculosis and Respiratory Diseases"},{"key":"10.7717\/peerj.20343\/ref-18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.omto.2021.02.004","article-title":"Molecular profiles of small cell lung cancer subtypes: therapeutic implications","volume":"20","author":"Schwendenwein","year":"2021","journal-title":"Molecular Therapy\u2014Oncolytics"},{"issue":"2","key":"10.7717\/peerj.20343\/ref-19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/onco1020010","article-title":"Pre-treatment C-reactive protein predicts survival in small cell lung cancer patients","volume":"1","author":"Stensvold","year":"2021","journal-title":"Onco"},{"issue":"1","key":"10.7717\/peerj.20343\/ref-20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13643-021-01585-w","article-title":"Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Winther-Larsen","year":"2021","journal-title":"Systematic Reviews"},{"issue":"45","key":"10.7717\/peerj.20343\/ref-21","doi-asserted-by":"publisher","first-page":"e35962","DOI":"10.1097\/MD.0000000000035962","article-title":"Prognostic value of pretreatment modified Glasgow prognostic score in small cell lung cancer: a meta-analysis","volume":"102","author":"Xie","year":"2023","journal-title":"Medicine"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20343.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20343.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:56:07Z","timestamp":1762764967000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":21,"alternative-id":["10.7717\/peerj.20343"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20343","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"e20343"}}